CFM
MRNA icon

Catalyst Funds Management’s Moderna MRNA Stock Holding History

Catalyst Funds Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
20,976
-34,387
-62% -$1.78M 0.08% 233
2026
Q1 		$2.81M Buy
+55,363
New +$2.58M 0.48% 49
2025
Q3 		– Sell
-22,410
Closed -$618K – 593
2025
Q2 		$618K Buy
+22,410
New +$590K 0.17% 166
2025
Q1 		– Sell
-35,200
Closed -$1.46M – 541
2024
Q4 		$1.46M Buy
+35,200
New +$1.68M 0.36% 58

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Catalyst Funds Management's MRNA Position: Q2 2026 in Review

Catalyst Funds Management reduced its Moderna (MRNA) stake by 62% in Q2 2026, selling an estimated $1.78M and leaving 20,976 shares worth $1.47M. The position accounts for 0.08% of the portfolio, ranked #233.

Catalyst Funds Management first reported a position in MRNA in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.81M in Q1 2026. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Catalyst Funds Management held 20,976 shares of Moderna worth $1.47M as of Q2 2026.
  • Catalyst Funds Management sold 34,387 Moderna shares in Q2 2026, an estimated $1.78M.
  • Moderna made up 0.08% of Catalyst Funds Management's portfolio in Q2 2026, its #233 holding.
  • Catalyst Funds Management first reported a position in Moderna in Q4 2024 and has held it in 4 quarters since.
  • Catalyst Funds Management's Moderna position peaked at $2.81M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.